<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543331</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258ADE02</org_study_id>
    <nct_id>NCT04543331</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration</brief_title>
  <acronym>BLUE SKY</acronym>
  <official_title>OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, observational, non-interventional, multicenter, open-label,&#xD;
      single arm study in nAMD patients being treated for nAMD with brolucizumab according to the&#xD;
      SmPC.&#xD;
&#xD;
      An observational study design, without a strict, mandated visit schedule or mandated&#xD;
      treatment regimen was chosen as the most appropriate to collect available data in a real life&#xD;
      setting. For that reason, this NIS does not impose a therapy protocol, diagnostic/therapeutic&#xD;
      procedure or a visit schedule. The diagnostic or monitoring procedures are only those&#xD;
      ordinarily applied to the therapeutic strategy and to routine clinical care and will take&#xD;
      place as per investigator's discretion. This includes e.g. visit frequency, injection&#xD;
      frequency and types of assessments performed - only data from routine medical practice will&#xD;
      be collected as part of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BLUE SKY consists of the two main study modules DEEP BLUE (Observational stuDy to Evaluate&#xD;
      fluid resolution and Effectiveness in Patients receiving Beovu (broLUcizumab) in neovascular&#xD;
      age-related macular dEgeneration) and BIRL (Brolucizumab In Real Life).&#xD;
&#xD;
      Patients will be enrolled at approximately 32 centers, which will be representatively&#xD;
      distributed amongst the 16 German federal states. This will ensure to reflect all&#xD;
      state-specific health insurance laws and guidelines. Naïve and pre-treated patients will be&#xD;
      included after decision to start treatment with brolucizumab and consent is given. Out of the&#xD;
      patients, 1/3 should be pre-treated and 2/3 naïve. All patients will be documented for the&#xD;
      DEEP BLUE study module (Full Analysis Set).&#xD;
&#xD;
      For the BIRL module, only naïve patients enrolled in 7 selected centers will be documented.&#xD;
      All these centers are equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze&#xD;
      BIRL specific objectives in a comparable setting. Only images from routine medical practice&#xD;
      will be collected as part of the study.&#xD;
&#xD;
      The study eye will be defined as the first eye treated during the study, the other eye will&#xD;
      be considered as fellow eye. If both eyes are treated at baseline, the eye with the worse&#xD;
      visual acuity will be chosen as the study eye (if the visual acuity is measured equal, the&#xD;
      treating ophthalmologist defines the study eye upon his discretion).&#xD;
&#xD;
      The prospective observation period per patient will be up to 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">November 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) in the study eye.</measure>
    <time_frame>month 12</time_frame>
    <description>This Oucome Measure is part of the Deep Blue module. This primary study objective will be addressed considering treatment naïve and pre-treated patient eyes included in the study, analyzed as two independent groups (naïve and switch).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in visual actuity (VA) in the study eye considering treatment naïve subgroup</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Mean change in visual actuity (VA) under clinic specific routine treatment schemes Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes.&#xD;
BIRL module</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphological CNV-Changes in the study eye considering treatment naïve subgroup</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Morphological Choroidal Neovascularization (CNV)-Changes under clinic specific routine treatment schemes Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes.&#xD;
BIRL module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluid resolution after initiation of brolucizumab</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Actuity (VA) change from baseline</measure>
    <time_frame>Baseline, month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Choroidal Neovascularization (CNV) morphology (BIRL) and activity</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections and total number of visits</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the distribution of injection intervals</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Spectral Contrast Optical Coherence Tomography (SC-OCTs) done</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the patients switching to another antivascular endothelial growth factor (anti-VEGF)</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of brolucizumab</measure>
    <time_frame>month 24</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Neovascular Age-related Macular Degeneration (nAMD)</condition>
  <arm_group>
    <arm_group_label>treatment naïve patients</arm_group_label>
    <description>Patients being the first time treated for nAMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-treated patients</arm_group_label>
    <description>Patients already being treated for nAMD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brolucizumab</intervention_name>
    <description>There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>pre-treated patients</arm_group_label>
    <arm_group_label>treatment naïve patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being treated for nAMD with brolucizumab will be enrolled in the study upon&#xD;
        signing an informed consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The unit of analysis is patient-eye, i.e. all criteria should be applied to the study eye,&#xD;
        unless otherwise specified. Patients will be included in the study if they fulfil the&#xD;
        following requisites:&#xD;
&#xD;
          1. Diagnosis of nAMD&#xD;
&#xD;
          2. Male and Female patients with ≥40 years of age at index&#xD;
&#xD;
          3. Decision to treatment with brolucizumab at baseline visit&#xD;
&#xD;
          4. Signed written informed consent&#xD;
&#xD;
          5. Patients for whom a therapy with brolucizumab is medically indicated&#xD;
&#xD;
          6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye&#xD;
             at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients that have any contraindication and are not eligible for treatment with&#xD;
             brolucizumab as according to the SmPC&#xD;
&#xD;
          2. Patients treated for RVO, DME, mCNV, or have diagnoses of diabetes-related macular&#xD;
             degeneration within 6 months prior to the index date&#xD;
&#xD;
          3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index&#xD;
             date&#xD;
&#xD;
          4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total&#xD;
             area of fibrosis &gt;50% of the total lesion in the study eye at Screening&#xD;
&#xD;
          5. Any active intraocular or periocular infection or active intraocular inflammation in&#xD;
             either eye at index date&#xD;
&#xD;
          6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index&#xD;
             date)&#xD;
&#xD;
          7. Any medical or psychological condition in the treating physician's opinion which may&#xD;
             prevent the patient from the 24 months study participation&#xD;
&#xD;
          8. Patients participating in parallel in an interventional clinical trial&#xD;
&#xD;
          9. Patients participating in parallel in any other NIS generating primary data for an&#xD;
             anti-VEGF drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>199 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luedenscheid</city>
        <state>NRW</state>
        <zip>58507</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breisach am Rhein</city>
        <zip>79206</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glauchau</city>
        <zip>08371</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hösbach</city>
        <zip>63768</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mutterstadt</city>
        <zip>67112</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17036</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93 047</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schoenebeck</city>
        <zip>39218</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torgau</city>
        <zip>04860</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beovu</keyword>
  <keyword>Brolucizumab</keyword>
  <keyword>nAMD</keyword>
  <keyword>non-interventional trial</keyword>
  <keyword>effectiveness</keyword>
  <keyword>fluid resolution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

